About NeuroEM
NeuroEM Therapeutics® is a Tampa-based medical device company committed to developing, clinically testing, and marketing Transcranial Electromagnetic Treatment (TEMT) in the Radio Frequency spectrum – also known as TRFT – to effectively prevent and treat Alzheimer’s disease and other neurodegenerative diseases and extend healthy longevity.
Clinical results indicate that our non-invasive bioengineered technology has the potential to stop and reverse the progressive memory impairment of Alzheimer’s disease.
First-in-class device designed to fight Alzheimer’s
NeuroEM Therapeutics’ “first-in-class” MemorEM™ device was designed to be comfortably worn on the head to administer TEMT / TRFT during daily in-home treatment.
Our pioneering TEMT technology has shown extraordinary promise against Alzheimer’s in all completed preclinical and clinical studies.
The electromagnetic waves emanating from multiple emitters in the MemorEM head cap disaggregate toxic protein ‘oligomers’ within neurons throughout the brain. Since these oligomers are increasingly believed to be the root cause of Alzheimer’s disease, we believe the MemorEM head device will directly attack the Alzheimer’s disease process.
TEMT has two additional mechanisms of action that attack Alzheimer’s and other diseases of aging, and could increase healthy longevity – TEMT re-balances the immune system in both brain and blood and TEMT increases the energy production of brain cells.
Since most diseases of aging appear to involve at least one of these three mechanisms, their prevalence and severity could be lessened by TEMT, resulting in increased healthy longevity.
NeuroEM’s MemorEM device will be available through neurologists and other health professionals who diagnose memory disorders once we complete our pivotal trials and receive FDA approval.
Leadership Team
-
Chuck Papageorgiou
Chief Executive Officer
-
Edward Goodwin, Ph.D.
Chief Scientist
-
Amanda Patanow
Chief Marketing
& Product Officer -
Tracy Ingram
Chief Operating
& Information Officer -
Chuanhai Cao, MPH, PhD.
Head of Research
-
Marilyn Thompson
Chief Financial Officer
-
Rob Baranowski
Sr. Engineer
Product Development -
Patty Meagher
Community Advocate
Partners and Collaborators
-
Left Coast Engineering
Rob Baranowski,
Senior Engineering Project Lead -
RF Exposure Lab
Jay Moulton,
Vice-President -
Ocotillo Electromagnetics
David Wittwer, Ph.D.
Richard Ziolkowski, Ph.D. -
Remarkable Technologies
Eric Knight,
President
-
USF Health/Byrd Alzheimer’s Institute
Amanda Smith, M.D.
-
Axiom Clinical Research of Florida
Susan Steen, M.D.
Haitham Abulaban, MBBS, CCRC -
Invicro/Konica Minolta
Gary Wisniewski, Ph.D.
Lino Becerra, M.D. -
MegaNano Biotech Inc.
Chuanhai Cao, Ph.D.
-
University of South Florida
Dr. Chuanhai Cao, Ph.D.
Ziaopeng Li, Ph.D.
Jing Wang, Ph.D.
Directors & Advisors
Jonathan Gordon
Chairman of the Board
Jon is a co-founder and managing partner of Stage One Ventures an early-stage venture capital firm, founded in 2006. He has been a successful executive, entrepreneur, and investor for over 30 years. He has been at the forefront of many historic market and technological changes in the high-tech global economy. Jon led Investments in e-Centives (sold to Catalina Marketing), AdelaVoice, Marxent Labs, Maple Farm Media, Carvoyant, Par Elastic, Instream, Veloxum, XPeerient, Delfigo Security, Wing Power, Phantom Alert, OnePin, Cuesol (sold to MobileLime), go2 (merged with 80108), SiteWit and Auspice (sold to Arris), SiteWit, and KiteDesk.
Jon is an accomplished executive, entrepreneur, and investor with over 40 years of experience in building technology companies from early and mid-stage to successful exits. His expertise spans enterprise software, system software, semiconductors, and instrumentation industries. Jon is adept at enhancing shareholder value through business development, establishing sales and market channels, ensuring timely product development, and managing operations cost-effectively to achieve profitability. Moreover, he has specialized knowledge in intellectual property monetization and maintains a wide network of high-level global relationships.
Mitch Lairmore
Director and Proxy for Dr. Arendash
Mitch Lairmore has a strong background in business development, strategic planning, and market research, with extensive experience in the commercialization of technology. He has led product development teams and supported small companies in obtaining SBIR grants from NASA, the US Air Force, and the NSF. As a staff consultant, Mitch provided commercialization assistance to projects funded by the US Navy, the Department of Energy, the National Science Foundation, the Department of Transportation, and the Department of Homeland Security.
Before these roles, he was a subcontractor to a prime contractor for major agencies such as the National Institute of Health, the Department of Energy, and the Environmental Protection Agency. At Eastman Kodak, Mitch served as a business development director, where he was responsible for strategic planning for new products and intellectual property licensing. He co-founded a venture within Kodak’s New Opportunity Development initiative and managed a significant data storage product development effort, securing partnerships and funding.
Mitch was also a board member for a Kodak Ventures Group company, guiding it to profitability. He holds a Certified Global Business Professional certification through the National Association of Small Business International Trade Educators and has assisted small businesses in expanding their international reach. Mitch earned an MBA from the William E. Simon Graduate School of Business Administration at the University of Rochester and a B.S. in Industrial Engineering from the University of Iowa.
Gary Arendash, Ph.D.
Founder & Scientist Emeritus
Dr. Arendash served as a Full Professor and Research Professor at the University of South Florida for 30 years. During his final six years there, he directed the Florida Alzheimer’s Disease Research Center’s Animal Core and one of its three principal research initiatives. Specializing in the development of Alzheimer's disease therapeutics, Dr. Arendash has published over 120 peer-reviewed articles in first-tier journals, such as Science, Nature, and the Journal of Alzheimer’s Disease, where he served as Senior Editor until 2017. During his tenure at USF, he secured $5 million in research funding from external agencies, including the National Institutes of Health (NIH) and the Alzheimer’s Disease and Related Disorders Association (ADRDA). Dr. Arendash was among the pioneers to demonstrate that Alzheimer's Disease begins in the brain decades before its clinical diagnosis. His landmark study in 2010 provided initial evidence that electromagnetic treatment induces cognitive benefits in Alzheimer's mice through multiple disease-modifying mechanisms. He further advanced this promising pre-clinical research by conducting three clinical studies from 2019 to 2023, which demonstrated the safety and efficacy of the technology he developed against Alzheimer’s. Dr. Arendash received his Ph.D. in Neuroscience/Physiology from the University of California, San Francisco (UCSF) and completed his post-doctoral research at UCLA’s Brain Research Institute before joining the University of South Florida faculty.
Lloyd Marks, MD, MBA, FACC
Medical Advisor
Dr. Marks is a pediatric cardiologist, electrical engineer, MBA, and inventor. Renowned for his innovation in the medical field, he boasts over 20 medical device patents, the majority of which have been successfully licensed to various industry leaders. As an entrepreneur, Dr. Marks has founded three startup companies, including one currently commercializing his medical invention. He is also a committed mentor, guiding student startups, and serves as an advisor to academic institutions, inventors, corporations, and investors. He regularly supports investors’ conducting due diligence and patent attorneys regarding the assessment, protection, and commercialization of medical technology. Dr. Marks completed his Bachelor of Science in Electrical and Electronics Engineering at the Massachusetts Institute of Technology, his MD at the University of Michigan Medical School, and an MBA for Physician Executives at the University of Tennessee, Knoxville.